Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.32 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3054957 | 0.84 | HTR7 (0.44) | HTR7HSD17B10HMGB1 | |
| SCHEMBL1491958 | 0.81 | PARP1 (0.34) | KDM4EALDH1A1HPGDENPP2HSD17B10 | |
| SCHEMBL519233 | 0.81 | ALDH1A1 (0.39) | KDM4EALDH1A1HPGDENPP2HSD17B10 | |
| SCHEMBL16236670 | 0.79 | KDM4E (0.32) | KDM4EALDH1A1HPGDENPP2HSD17B10 | |
| SCHEMBL11865883 | 0.79 | AKR1B1 (0.42) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL9825071 | 0.75 | PTGDR (0.36) | KDM4EALDH1A1HPGDENPP2HSD17B10 | |
| SCHEMBL7967187 | 0.75 | PTPN1 (0.47) | SMN1; SMN2 | |
| SCHEMBL2213722 | 0.73 | DHODH (0.36) | — | |
| SCHEMBL27591550 | 0.73 | GABRP (0.43) | KDM4EALDH1A1HPGDHSD17B10MAPT | |
| SCHEMBL10866762 | 0.72 | BID (0.46) | KDM4EALDH1A1HSD17B10MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 373 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1761554-A2 | PEPTIDE ANTIBIOTICS AND METHODS FOR MAKING SAME | Biosource Pharm, Inc. (US) | 2007-03-14 | — | — | EP | claimed |
| WO-2006083317-A2 | PEPTIDE ANTIBIOTICS AND METHODS FOR MAKING SAME | BIOSOURCE PHARM, INC. (US) | 2006-08-10 | — | — | WO | claimed |
| US-20260055150-A1 | GRAIL-1 PEPTIDE PRODUCTS AND METHODS | UNIV MICHIGAN (US) | 2026-02-26 | — | — | US | disclosed |
| EP-4680108-A1 | PEPTIDE MULTIMER PRODUCTS AND METHODS | The Regents of The University of Michigan (US) | 2026-01-21 | — | — | EP | disclosed |
| US-20250263685-A1 | OLIGOSACCHARIDES COMPRISING AN AMINOOXY GROUP AND CONJUGATES THEREOF | GENZYME CORPORATION | 2025-08-21 | — | — | US | disclosed |
| US-20250263439-A1 | HETERODIMERIC PEPTIDE REAGENTS AND METHODS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2025-08-21 | — | — | US | disclosed |
| EP-3660040-B1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME LLC (US) | 2025-06-18 | — | — | EP | disclosed |
| EP-4565333-A2 | GRAIL-1 PEPTIDE PRODUCTS AND METHODS | Regents of the University of Michigan (US) | 2025-06-11 | — | — | EP | disclosed |
| US-12269900-B2 | Inhibitors of β integrin-G protein α subunit binding interactions | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2025-04-08 | — | — | US | disclosed |
| US-20250073355-A1 | CD44-BINDING PEPTIDE REAGENTS AND METHODS | REGENTS OF THE UNIVERSITY OF MICHIGAN | 2025-03-06 | — | — | US | disclosed |
| US-20250051416-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME LLC (US) | 2025-02-13 | — | — | US | disclosed |
| WO-2007098420-A2 | PEPTIDES THAT BLOCK THE BINDING OF IGG TO FCRN | SYNTONIX PHARMACEUTICALS, INC. (US) | 2007-08-30 | — | — | WO | disclosed |
| EP-1819721-A1 | MICROCIN B17 ANALOGS AND METHODS FOR THEIR PREPARATION AND USE | Plant Bioscience Limited (GB) | 2007-08-22 | — | — | EP | disclosed |
| CN-101010336-A | Peptide antibiotics and process for preparing same | BIOSOURCE PHARM INC (US) | 2007-08-01 | — | — | CN | disclosed |
| EP-1761554-A2 | PEPTIDE ANTIBIOTICS AND METHODS FOR MAKING SAME | Biosource Pharm, Inc. (US) | 2007-03-14 | — | — | EP | disclosed |
| WO-2006083317-A9 | PEPTIDE ANTIBIOTICS AND METHODS FOR MAKING SAME | BIOSOURCE PHARM INC (US) | 2007-03-01 | — | — | WO | disclosed |
| WO-2006083317-A2 | PEPTIDE ANTIBIOTICS AND METHODS FOR MAKING SAME | BIOSOURCE PHARM, INC. (US) | 2006-08-10 | — | — | WO | disclosed |
| WO-2006054102-A1 | MICROCIN B17 ANALOGS AND METHODS FOR THEIR PREPARATION AND USE | PLANT BIOSCIENCE LIMITED (GB) | 2006-05-26 | — | — | WO | disclosed |
| EP-1627926-A1 | A method to reduce false positive results | Roche Diagnostics GmbH (DE) | 2006-02-22 | — | — | EP | disclosed |
| CN-1737165-A | A method to reduce false positive results | HOFFMANN LA ROCH (CH) | 2006-02-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260055150-A1 | GRAIL-1 PEPTIDE PRODUCTS AND METHODS | TP53, TP53BP1, DDIT3 | HTR7 4529/4885KDM4E 2893/4885ALDH1A1 3552/4885 |
| US-20250263439-A1 | HETERODIMERIC PEPTIDE REAGENTS AND METHODS | ERBB2, EGFR, ERBB3 | HTR7 4358/4885KDM4E 4714/4885ALDH1A1 4117/4885 |
| US-20250263685-A1 | OLIGOSACCHARIDES COMPRISING AN AMINOOXY GROUP AND CONJUGATES THEREOF | MAN2B1, MAN1B1, GAA | HTR7 3710/4885KDM4E 2044/4885ALDH1A1 3254/4885 |
| US-20250051416-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | INSR, GPR119, IRS1 | HTR7 340/4885KDM4E 4815/4885ALDH1A1 4716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.